Institutional shares held 33.8 Million
453K calls
931K puts
Total value of holdings $272M
$3.65M calls
$7.5M puts
Market Cap $404M
49,861,500 Shares Out.
Institutional ownership 67.72%
# of Institutions 160


Latest Institutional Activity in EBS

Top Purchases

Q3 2024
Marshall Wace, LLP Shares Held: 2.49M ($20.2M)
Q3 2024
State Street Corp Shares Held: 1.91M ($15.5M)
Q3 2024
Oak Hill Advisors LP Shares Held: 1.11M ($9.02M)
Q3 2024
American Century Companies Inc Shares Held: 1.73M ($14M)
Q3 2024
Trexquant Investment LP Shares Held: 440K ($3.57M)

Top Sells

Q3 2024
Charles Schwab Investment Management Inc Shares Held: 2.22M ($18M)
Q3 2024
Jpmorgan Chase & CO Shares Held: 643 ($5.21K)
Q3 2024
Fuller & Thaler Asset Management, Inc. Shares Held: 156K ($1.26M)
Q3 2024
Jane Street Group, LLC Shares Held: 147K ($1.19M)
Q3 2024
Citadel Advisors LLC Shares Held: 20.5K ($166K)

About EBS

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.


Insider Transactions at EBS

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
231K Shares
From 13 Insiders
Grant, award, or other acquisition 231K shares
Sell / Disposition
102K Shares
From 9 Insiders
Open market or private sale 52.2K shares
Payment of exercise price or tax liability 45.3K shares
Sale (or disposition) back to the issuer 4.01K shares

Track Institutional and Insider Activities on EBS

Follow Emergent BioSolutions Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells EBS shares.

Notify only if

Insider Trading

Get notified when an Emergent Bio Solutions Inc. insider buys or sells EBS shares.

Notify only if

News

Receive news related to Emergent BioSolutions Inc.

Track Activities on EBS